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The molecular mechanisms contributing to the development of cutaneous papillomas (CPs) and cutaneous
squamous cell carcinomas (CSCCs) are still poorly understood, limiting the ability to identify molecular suit-
able targets for the development of novel therapies. Persistent activation of the phosphatidylinositol 3-kinase/
Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signalling pathway is a component of epidermal
carcinogenesis in dogs. The present study describes the immunohistochemical expression pattern of two key
regulatorymolecules involved in the PI3K/Akt/mTOR signalling pathway, phosphorylated epidermal growth
factor receptor (pEGFR)Tyr1068 and phosphatase and tensin homologue (PTEN), in samples of normal canine
epidermis, CP, preneoplastic epidermis and CSCC using tissue microarrays to determine whether the deregu-
lated activity of these molecules is involved in the pathogenesis of these relevant epidermal tumours of dogs.
Expression of pEGFR and PTEN was dysregulated in most samples of CP, preneoplastic epidermis and
CSCC. Overexpression of pEGFR, together with decreased expression of PTEN, may facilitate the progression
of some canine CPs and CSCCs by deregulation of the key cellular functions in which the PI3K/Akt/mTOR
signalling pathway is involved. These findings suggest that the PI3K/Akt/mTOR signalling molecules may be
potential therapeutic targets for canine patients with CP and CSCC.
 2019 Elsevier Ltd. All rights reserved.Keywords: dog; epidermal carcinogenesis; mTOR signalling pathway; tissue microarrayIntroduction
Clinically relevant epidermal tumours in dogs include
cutaneous papilloma (CP) and cutaneous squamous
cell carcinoma (CSCC) (Gross et al., 2005;
Goldschmidt and Goldschmidt, 2016). CP is a
common benign tumour of the dog skin usually
associated with canine papillomavirus infectionondence to: B. L. Sanz Ressel (e-mail: lsanzressel@fcv.unlp.edu.
75/$ - see front matter
doi.org/10.1016/j.jcpa.2019.10.005(Gross et al., 2005; Goldschmidt and Goldschmidt,
2016). Viral papillomas show typical cytopathic
effects associated with a viral aetiology in the
keratinocytes, while papillomatous lesions that do
not show the typical cellular changes are known as
squamous papillomas (Goldschmidt et al., 1988).
Despite the fact that most CPs resolve spontaneously
within weeks to months, treatment is necessary for
some patients (Miller et al., 2013). CSCC is the second
most frequent malignant tumour of the canine skin 2019 Elsevier Ltd. All rights reserved.
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2016). Traditional risk factors for CSCC include
prolonged sun exposure and unpigmented and
lightly haired skin at the tumour site (Goldschmidt
and Goldschmidt, 2016). Solar-induced carcinomas
are usually preceded by a preneoplastic epidermal
lesion known as actinic keratosis, which spontane-
ously progresses into CSCC (Gross et al., 2005). How-
ever, CSCCs that are not solar-induced can develop
anywhere on the skin, including the subungual region
(Gross et al., 2005). Although CSCCs are generally
locally invasive with metastasis that occurs later in
disease, some CSCCs have more aggressive behaviour
(Gross et al., 2005; Wobeser et al., 2007; Miller et al.,
2013; Goldschmidt and Goldschmidt, 2016). Even
though there has been considerable progress in the
management of CSCC, treatment options are still
limited, and patients with advanced CSCC
frequently fail to respond to standard therapies
(Hauck, 2012; Miller et al., 2013; Goldschmidt and
Goldschmidt, 2016).
The molecular mechanisms underlying the devel-
opment of CP and CSCC in dogs are still poorly un-
derstood, limiting our ability to identify molecular
targets for the development of novel therapies for
these patients. In this regard, we have recently shown
that persistent activation of the phosphatidylinositol
3-kinase/Akt/mammalian target of rapamycin
(PI3K/Akt/mTOR) signalling pathway is a frequent
molecular event during canine epidermal carcinogen-
esis, pointing to this signalling pathway as a potential
therapeutic target (Sanz Ressel et al., 2019a, b). This
signalling pathway has received considerable
attention, as the use of mTOR inhibitors have
shown promising results in the treatment of CP and
CSCC in murine models (Amornphimoltham et al.,
2004, 2008; Athar and Kopelovich, 2011; Checkley
et al., 2011, 2014; Callejas-Valera et al., 2016). The
activation of the PI3K/Akt/mTOR signalling
pathway may result from the activation of the
epidermal growth factor receptor (EGFR), which
leads to its phosphorylation on specific tyrosine
residues including tyrosine 1068 (Downward et al.,
1984). Phosphorylated EGFR (pEGFR) promotes
the activation of PI3K, which mediates the phosphor-
ylation of phosphatidylinositol 4,5-bisphosphate
(PIP2) to generate phosphatidylinositol [3e5]-tri-
sphosphate (PIP3). In turn, PIP3 activates the
serine/threonine kinase Akt, which promotes critical
cellular processes such as cell cycle progression, cell
growth and cell fate decisions by the activation of
mTOR. The PI3K/Akt/mTOR signalling pathway
is strictly regulated by several negative feedback
mechanisms, including the phosphatase and tensin
homologue (PTEN), which shuts off PI3K signallingby dephosphorylating PIP3 to PIP2 (Luo et al., 2003).
The enhanced activity of the PI3K/Akt/mTOR sig-
nalling pathway may result from the overactivity of
EGFR and/or downregulation of the expression of
the tumour suppressor protein PTEN, as it was sug-
gested in man (Molinolo et al., 2009; Janus et al.,
2017). However, the activity of these key regulatory
proteins of the PI3K/Akt/mTOR signalling
pathway in relevant epidermal tumours of dogs,
such as CP and CSCC, is still unknown.
The aim of this study was to evaluate the immuno-
histochemical expression pattern of two key regulatory
molecules involved in the PI3K/Akt/mTOR signalling
pathway, pEGFRTyr1068 and PTEN, in samples of
normal epidermis, CP, preneoplastic epidermis and
CSCC using tissue microarrays (TMAs), in order to
determine whether the deregulated expression of these
molecules is involved in the pathogenesis of clinically
relevant epidermal tumours in dogs.Materials and Methods
Tissue Microarray
Paraffin wax blocks of formalin-fixed tissues from
normal epidermis, CP, preneoplastic epidermis and
CSCC of dogs were retrieved from the archives of
the Instituto de Patologı́a Dr. Bernardo Epstein, Fac-
ultad de Ciencias Veterinarias, Universidad Nacional
de La Plata, Buenos Aires, Argentina. The tissue sam-
ples were submitted between 2006 and 2014 and had
been processed routinely and embedded in paraffin
wax. Sections had been stained with haematoxylin
and eosin (HE) for histopathological diagnosis. Clin-
ical information was also available for review.
In order to determine the tissue suitability for inclu-
sion in this study, HE-stained sections from each sam-
ple were re-evaluated. A total of 17 samples of normal
epidermis, 41 cases of CP, 12 cases of preneoplastic
epidermis (actinic keratosis and dysplastic epidermis
contiguous to CSCCs) and 150 cases of CSCC were
selected. Tumours were classified according to the in-
ternational histological classification of epithelial tu-
mours of the skin of domestic animals of the World
Health Organization (Goldschmidt et al., 1988).
The distribution of CP cases, based on their histolog-
ical features, were 28 viral papillomas and 13 squa-
mous papillomas. Each HE-stained slide was
mapped under microscopical observation to select
and circle with a water-resistant coloured pen the
appropriate tissue areas from each donor block to
build the TMA.
Three different array blocks were engineered and
constructed (the first containing 90 cores from
CSCC; the second containing 89 cores from CSCC,
28 B.L. Sanz Ressel et al.preneoplastic epidermis and normal epidermis; and
the last containing 41 cores from CP), taking the
approach described by Hewitt (2004), using a semi-
automatic tissue arrayer (TMArrayer, Pathology
Devices Inc., San Diego, California, USA), and a
core diameter of 1 mm (one core per case). Ten addi-
tional samples of normal tissues (i.e. dog skin, human
liver, dog lymph node, human thyroid and human
cerebellum) and neoplastic tissues (i.e. dog skin, hu-
man skin, dog mammary gland, human lung and hu-
man colon) were included on each array block as
negative and positive controls for immunohistochem-
istry (IHC) (Hewitt, 2004; Molinolo et al., 2007).
HE-stained sections (5 mm) were taken from each
TMA to evaluate the tissue preservation and quality
of each core. The histological assessment performed
showed a good quality of TMA sections. According
to the tissue representativity, 15/17 cores of normal
epidermis, 36/41 cores of CP, 10/12 cores of preneo-
plastic epidermis and 140/150 cores of CSCCs were
selected for subsequent analyses (Sanz Ressel et al.,
2019a, b).Immunohistochemistry
IHC was performed using antibodies against
pEGFRTyr1068 (phosphorylated EGFR in Tyr1068,
rabbit monoclonal antibody, prediluted; Biocare
Medical, Pacheco, California, USA) and PTEN
(mouse monoclonal antibody, prediluted; Biocare
Medical). The negative control was TMA slides pro-
cessed for IHC for which the primary antibody was
substituted by an isotype-specific immunoglobulin
(according to the primary antibody used: rabbit
[DA1E]mAb IgGXP Isotype Control; Cell Signal-
ling Technologies, Danvers, Massachusetts, USA; or
mouse [G3A1] mAb IgG1 Isotype Control; Cell Sig-
nalling Technologies). A sample of canine CSCC
served as a positive control.
TMA sections (5 mm) were placed onto positively
charged glass microscope slides. Slides were placed
into an oven at 65C for 30 min to melt the paraffin
wax and then immersed in Safeclear II (Fisher Scien-
tific, Hampton, New Hampshire, USA) for 5 min
(three times) for dewaxing and hydrated through suc-
cessive passages in descending concentrations graded
alcohols. In order to block endogenous peroxidase,
slides were incubated in H2O2 3% in 70% ethanol
for 30min and washed three times with distilled water
for 5min. For antigen retrieval, slides were placed in a
container with 10 mM sodium citrate and heated in a
microwave oven (800 Watts) for 20 min (2 min at
100% power and 18 min at 20% power). The slides
were allowed to cool for 15 min at room temperature,washed once with distilled water and then three times
with phosphate buffered saline (PBS). Sections were
incubated in blocking solution (2.5% bovine serum
albumin in PBS) for 30 min at room temperature.
Excess blocking solution was discarded and the sec-
tions were incubated with the primary antibody
diluted in blocking solution at 4C overnight. After
washing with PBS, the slides were sequentially incu-
bated with biotinylated secondary antibody (accord-
ing to the primary antibody used: biotinylated goat
anti-rabbit IgG, BA-1000, diluted 1 in 400; Vector
Laboratories, Burlingame, California, USA; or bio-
tinylated goat anti-mouse IgG, diluted 1 in 400; Vec-
tor Laboratories) for 30 min. The slides were washed
with PBS for 5 min (three times) and incubated with
the avidinebiotin complex (Vectastain Elite ABC
Kit, PK-6100; Vector Laboratories) for 30 min at
room temperature. The slides were washed with
PBS and labelling was ‘visualized’ with 3, 30-diamino-
benzidine (SigmaFast tablets, D4168-50SET;
Sigma Chemical Co., St. Louis, Missouri, USA) to ef-
fect. The reaction was stopped in distilled water, and
the tissues were counterstained with Mayer’s haema-
toxylin, dehydrated in graded alcohols and mounted.
Sections were scanned with a 40 objective using
the Aperio CS ScanScope (Leica Biosystems Imag-
ing Inc., Buffalo Grove, Illinois, USA). The immuno-
histochemical expression of pEGFRTyr1068 and PTEN
was quantified using the Aperio image analysis algo-
rithms on the ImageScope viewing software. The
number of positive epidermal cells was counted for
each tissue core, expressing the results as the percent-
age of positive cells/total cells. According to these re-
sults, cores were divided into five categories: 0,<10%
of cells labelled; 1, 11e25% of cells labelled; 2,
26e50% of cells labelled; 3, 51e75% of cells labelled;
4, 76e100% of cells labelled (Molinolo et al., 2007).Statistical Analysis
Differences in immunohistochemical reactivity
between groups were analysed using the
KruskalleWallis test for non-Gaussian populations
(non-parametric analysis of variance; ANOVA) fol-
lowed by the Dunn’s post-test (Statgraphics soft-
ware, The Plains, Virginia, USA; P <0.05 and 95%
confidence).Results
Expression of pEGFRTyr1068 and PTEN in Normal
Epidermis
To determine whether expression of pEGFRTyr1068
and PTEN is dysregulated in canine epidermal tu-
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these proteins in normal epidermis (Fig. 1;
Supplementary Table 1). The immunodetection of
pEGFRTyr1068 showed a high number of positive
epidermal cells with membrane and cytoplasmic
labelling limited to the basal and spinous cell strata
(Fig. 2). PTEN immunolabelling revealed a low num-
ber of positive epidermal cells located in the basal and
spinous cell strata, showing a cytoplasmic expression
pattern (Fig. 3).Fig. 1. Quantitative analysis of immunohistochemistry for
pEGFRTyr1068 (A) and PTEN (B) in samples of normal
epidermis (NE), cutaneous papillomas (CP), preneoplas-
tic epidermis (PE) and cutaneous squamous cell carci-
nomas (CSCC). The number of positive epidermal cells
was expressed as the percentage of positive cells/total cells.
Score: 0, <10% of cells labelled; 1, 11e25% of cells
labelled; 2, 26e50% of cells labelled; 3, 51e75% of cells
labelled; 4, between 76 and 100% of cells labelled.Expression of pEGFRTyr1068 and PTEN in Cutaneous
Papilloma
CP samples showed a high number of epidermal cells
positive for pEGFRTyr1068 and PTEN (Fig. 1;
Supplementary Table 2). pEGFRTyr1068 labelling re-
vealed a membrane and cytoplasmic expression
pattern limited to the basal and spinous strata
(Fig. 2). PTEN immunolabelling showed a high cyto-
plasmic expression limited to the basal and spinous
strata inmost samples (Fig. 3), although lowexpression
of this protein was observed in some samples (12/36,
33.33%). The KruskalleWallis test showed no signifi-
cant differences in the percentage of labelled cells be-
tween normal epidermis and CP for pEGFRTyr1068 or
PTEN. Furthermore, no significant differences for
the selected regulatory proteins of the PI3K/Akt/
mTOR signalling pathway were found between viral
papillomas and squamous papillomas.Expression of pEGFRTyr1068 and PTEN in Preneoplastic
Epidermis and Cutaneous Squamous Cell Carcinoma
We finally explored the expression of pEGFRTyr1068
and PTEN in samples of preneoplastic epidermis
and CSCC (Fig. 1; Supplementary Tables 3 and 4).
pEGFRTyr1068 immunoreactivity was expressed in a
high number of epidermal cells in all preneoplastic
epidermal samples and in 90/140 (64.28%) CSCC
samples, showing membrane and cytoplasmic immu-
noreactivity in the epidermal cells of the basal and
spinous strata (Fig. 2). The immunodetection of
PTEN showed a high number of positive epidermal
cells in all preneoplastic epidermis samples and in
111/140 (79.29%) CSCC samples, for which cyto-
plasmic expression in the basal and spinous cell strata
was observed (Fig. 3). The KruskalleWallis test
showed significant differences in the percentage of
cells labelled for pEGFRTyr1068 between normal
epidermis and preneoplastic epidermis (P <0.01),
while no significant difference was found between
normal epidermis and CSCC. Furthermore, signifi-
cant differences in the percentage of cells expressing
PTEN were found between normal epidermis and
preneoplastic epidermis (P <0.01) and between
normal epidermis and CSCC (P <0.01). PTEN
showed no significant differences between CSCCs
based on tumour location.Discussion
The molecular mechanisms involved in the develop-
ment of CP and CSCC in dogs are still poorly under-
stood, limiting the ability to identify molecular targets
for the development of novel therapies for these pa-
tients. In this regard, characterization of relevant
Fig. 2. (A) Immunodetection of pEGFRTyr1068 in array cores of normal epidermis (NE), cutaneous papillomas (CP), preneoplastic
epidermis (PE) and cutaneous squamous cell carcinomas (CSCC). (B) pEGFRTyr1068 -positive cells (brown) show strong mem-
brane labelling and a cytoplasmic labelling pattern limited to the basal and spinous cell strata in samples of normal epidermis,
CP, preneoplastic epidermis and CSCC. Bars, 300 mm (A) and 50 mm (B).
30 B.L. Sanz Ressel et al.signalling molecules in a large number of tumour
samples under identical and standardized conditions
can help to identify the key molecular events involved
in canine epidermal tumourigenesis. In this study, we
have described the immunohistochemical expression
pattern of two key regulatory proteins of the PI3K/
Akt/mTOR signalling pathway, pEGFRTyr1068 and
PTEN, in normal canine epidermis, CP, preneoplas-Fig. 3. (A) Immunodetection of PTEN in array cores of preneopla
epidermis (PE) and cutaneous squamous cell carcinomas (C
(brown) in the basal and spinous cell strata in samples of n
300 mm (A) and 50 mm (B).tic epidermis andCSCC using TMA in order to deter-
mine whether the dysregulated expression of these
molecules is involved in epidermal tumourigenesis in
dogs.
The immunodetection of the selected regulatory
proteins of the PI3K/Akt/mTOR signalling pathway
in CP showed thatmost samples displayed a high level
of expression of pEGFRTyr1068, although lowstic epidermis (NE), cutaneous papillomas (CP), preneoplastic
SCC). (B) PTEN immunolabelling with a cytoplasmic reaction
ormal epidermis, CP, preneoplastic epidermis and CSCC. Bars,
pEGFR and PTEN in Canine Epidermal Tumours 31expression of this protein was also observed in some
samples. In this regard, previous studies have shown
that EGFR plays an important role in epidermal tu-
mourigenesis mediated by human papillomavirus
(HPV). Indeed, keratinocytes immortalized by
HPV exhibit the constitutive activation of EGFR
in vitro (Zyzak et al., 1994), while pharmacological in-
hibition of this receptor effectively blocks the growth
and survival of immortal keratinocytes in culture
(Ben-Bassat et al., 1997, 1999). Similarly,
Woodworth et al. (2000) showed that EGFR activa-
tion is important for the immortalization of mouse
keratinocytes by HPV, as well as for the progression
of these immortal cells to papillomas and carcinomas.
However, the fact that some papillomas showed
reduced or absent expression of pEGFRTyr1068 indi-
cates that, although EGFR activation could play an
important role in the development of canine CP, it
may not be strictly necessary. Indeed, all of the cases
in which the pEGFR was not detected were tumour
samples in which the mTOR signalling pathway
was persistently activated (Sanz Ressel et al.,
2019b). These findings are aligned with those
observed in mouse keratinocytes immortalized by
HPV, where treatment with the tumour promoter
12-O-tetradecanoylphorbol-13-acetate induced the
formation of papillomas even in grafts containing ker-
atinocytes not expressing EGFR (Woodworth et al.,
2000). These results suggest that the tumour progres-
sion of keratinocytes can also occur through pathways
independent of EGFR activation (Woodworth et al.,
2000). Similarly, the results obtained from study of
a murine model of epidermal carcinogenesis suggest
that once a determined stage of tumour growth has
been reached, the survival of the tumour cells can
be achieved by the activity of parallel growth pro-
moter pathways independent of EGFR (Dahlhoff
et al., 2011). Altogether these results provide further
evidence of the existence of still poorly understood
molecular alterations in the pathogenesis of CP in
dogs, which may lead to the EGFR-independent acti-
vation of growth promoter signalling pathways such
as the mTOR signalling pathway.
PTENwas expressed in the cytoplasm of cells of the
basal and spinous strata in most CP samples, but low
expression of this protein was observed in some sam-
ples. These findings may be related to the attempt
carried out by the tissue to restore the normal func-
tioning of the PI3K/Akt/mTOR signalling pathway
during epidermal tumourigenesis, while the tumour
suppressor functions of this molecule may be compro-
mised in some patients. Similarly, previous studies in
mice have shown that the decreased activity of PTEN
may be a frequent event during the tumour progres-
sion of epidermal keratinocytes (Segrelles et al.,2002). In this regard, Suzuki et al. (2003) demon-
strated through a genetically modified mouse model
that the deficiency of PTEN leads to a hyperprolifer-
ative epidermis and, consequently, to the develop-
ment of spontaneous tumours such as papillomas. In
this model, increased proliferation of the epidermal
keratinocyte was related to an increased activity of
the PI3K/Akt/mTOR signalling pathway (Suzuki
et al., 2003). In connection with the findings that
show that a reduced expression of PTEN may play
an important role during epidermal tumourigenesis
by the persistent activation of the PI3K/Akt/mTOR
signalling pathway, we observed that the tumours ex-
hibiting reduced PTEN labelling were positive for the
phosphoproteins of the mTOR signalling pathway
(Sanz Ressel et al., 2019b).
We then explored the expression pattern of the two
regulatory proteins of the PI3K/Akt/mTOR signal-
ling pathway in samples of preneoplastic epidermis
and CSCC. The immunodetection of pEGFRTyr1068
showed that the persistent activation of this receptor
is a frequent event in most canine samples of preneo-
plastic epidermis and CSCC, similar to previous re-
sults reported in man (Kikuchi et al., 1990; Nazmi
et al., 1990). However, Uribe and Gonzalez (2011)
showed that only 73% of human CSCCs analysed
overexpressed EGFR. Similarly, Fogarty et al.
(2007) showed that only 43% of humanCSCCs exam-
ined showed EGFR expression and only 53% of those
showed activation of the receptor. These observations
are aligned with a recent report describing that the
EGFR was expressed in 90% of human CSCCs evalu-
ated, but only 35% of them showed overexpression
(Ca~nueto et al., 2017). These findings are similar to
those of the present study, in which only 64% of
CSCCs showed expression of pEGFRTyr1068. These re-
sults suggest that the activation of EGFR is an impor-
tant event during the malignant transformation of
epidermal keratinocytes in dogs, but it may not be
strictly necessary. Furthermore, a high level of
EGFR activation may not be required for PI3K/
Akt/mTOR activation (Joseph et al., 2014). In this re-
gard, we recently showed that the activation of pS6,
the downstream target of the PI3K/Akt/mTOR sig-
nalling pathway, increased in most CSCCs (Sanz
Ressel et al., 2019a). We now show that the enhanced
activity of the mTOR signalling pathway may not be
correlatedwith the activity of EGFR, since some of the
cases in which pS6 was detected were tumour samples
in which EGFR was not persistently activated. These
findings are aligned with those reported in human
squamous cell carcinomas of the head and neck
(Molinolo et al., 2007), which raises the question of
the possible existence of EGFR-independent routes
that can promote the growth and survival of tumour
32 B.L. Sanz Ressel et al.cells. Altogether, these findings suggest that EGFR
could represent a potential therapeutic target only in
CSCC canine patients with activation of this receptor.
The immunodetection of PTEN showed high
expression in all preneoplastic epidermal samples,
while its expression was reduced or absent in some
CSCC samples. These findings may be related to an
attempt by the tissue to restore the normal functioning
of the PI3K/Akt/mTOR signalling pathway during
the early stages of malignant transformation of canine
epidermal keratinocytes. These results disagree with
those reported in mice, which suggest that PTEN is
not important during the initial stages of murine
epidermal carcinogenesis (Segrelles et al., 2002).
Furthermore, the fact that PTEN expression was
reduced or absent in some CSCC samples indicates
that the tumour suppressor functions of this molecule
may be compromised during the malignant transfor-
mation of epidermal keratinocytes, similar to that pre-
viously reported in mice (Segrelles et al., 2002).
Likewise, the absence of PTEN was related to the
development of spontaneously arising cutaneous squa-
mous cell carcinomas in a murine model of skin carci-
nogenesis (Suzuki et al., 2003). In thismodel, increased
proliferation and resistance to apoptosis of epidermal
keratinocytes was associated with increased activity
of downstream molecules of the mTOR signalling
pathway (Suzuki et al., 2003). The fact that we have
previously shown that most of these CSCC patients
overexpressed pS6 (Sanz Ressel et al., 2019a) supports
the hypothesis that the decrease of PTENexpression at
the tumour stage may cause the overactivity of the
PI3K/Akt/mTOR signalling pathway in some ani-
mals and, consequently, the deregulation of cellular
processes in which this signalling pathway is involved.
In summary, we show here that the expression of
pEGFR and PTEN is dysregulated during epidermal
carcinogenesis in dogs. In this regard, overexpression
of pEGFR and/or the decrease of expression of PTEN
may facilitate the progression of canine CP andCSCC
by deregulation of the key cellular functions in which
the PI3K/Akt/mTOR signalling pathway is involved.
Furthermore, the fact that EGFR activation was ab-
sent in some canine patients suggests that therapeutic
approaches aimed at modulating the growth and sur-
vival of tumour cells by the use of EGFR inhibitors
would be ineffective as sole therapeutic agents in
some CP and CSCC patients, as it was previously sug-
gested in man (Molinolo et al., 2007).Acknowledgments
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